Latin America continues to move its R&D machinery against COVID-19

Latin American research institutions keep joining the global search for vaccines and treatments against COVID-19. The Center for Genetic Engineering and Biotechnology (CIGB), which belongs to Cuba’s state-owned pharmaceutical company BioCubaFarma, has designed a vaccine and is developing it in partnership with China’s Research and Development Center in the Industrial Zone of Yongzhou, Hunan. Similarly, Chile's Millennium Institute on Immunology and Immunotherapy (IMII) is set to produce a vaccine candidate in two months and to market it within one-and-a-half years. Brazil’s University of São Paulo (USP) earlier this month announced its own vaccine development project.

Mexico’s National Polytechnic Institute (IPN) is enrolling patients for a clinical trial (CT) evaluating its peptide extract Transferon on non-severe patients in the initial stages of COVID-19. The project expects to recruit hundreds of volunteers.

Argentina’s National University of Tucumán (UNT) is preparing a hydroxychloroquine CT on COVID-19, while four Brazil health institutions have partnered with the Ministry of Health (MoH) to evaluate hydroxychloroquine, azithromycin, and dexamethasone against mild, severe, and critical COVID-19 in 1,354 patients, with results expected in 60 to 90 days. Local drug maker EMS will participate supplying hydroxychloroquine and azithromycin.

Meanwhile, the Oswaldo Cruz Foundation (Fiocruz) has completed the first sequence of SARS-CoV-2 in Brazil’s northern region, finding 9 mutations compared to a sample from Wuhan, China. The team will now investigate whether these variations determine the severity of COVID-19 cases.


Recent news
The National Medical Products Administration (NMPA) last week revealed that Celgene’s Abraxane (paclitaxel, albumin bound) would lose its import clearance after agency inspectors uncovered manufacturing issues at the Fresenius Kabi plant responsible for manufacturing the drug. The news impacts Chinese biotech BeiGene Inc., which generated around USD 100 million with Abraxane in China as the drug's marketing agent under license from Celgene.
  • 1585666816337
  • China
Pfizer subsidiary Wyeth this week obtained a marketing approval from Brazil's National Health Surveillance Agency (ANVISA) for its iron replacement therapy Monofer (ferric derisomaltose), as GBI analysis shows.
Hugo Sigman, founder of of Argentina-based group Insud Pharma, last week commented on Argentina’s biopharmaceutical industry as the COVID-19 pandemic puts the health sector to test.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) released its Q4 2019 financial report.
According to GBI analysis, Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS) has published recent market approvals for Swiss major Novartis subsidiary Sandoz’s Arasamila (rituximab), Japan-based Daiichi Sankyo’s factor Xa (FXa) inhibitor Lixiana (edoxaban), and compatriot Takeda branch Baxalta’s antihemophilic Adynovate (rurioctocog alfa pegol).
GoBroad Healthcare Group broke ground on construction of a research hospital in Beijing’s Future Science Park this week.
Analytics Snapshot

Analytics Snapshot